Tag: business

ALBUQUERQUE, New Mexico, July 16, 2025 (GLOBE NEWSWIRE) -- As the medical aesthetics industry continues to experience exponential growth, many medspa owners and aesthetic providers find themselves overwhelmed — juggling clients, marketing, operations, and still struggling to generate consistent profits. Dr. Kalpana Sundar, a board-certified physician and nationally recognized aesthetic business strategist, is on a mission to change that. This August, she is bringing her signature Aesthetic Profit Accelerator Bootcamp to Albuquerque, New Mexico, from August 7–10, 2025 — a powerful four-day intensive seminar designed to help aesthetic professionals turn passion into predictable, scalable profit.

The report covers trends, drivers, tariffs, and regional growth in key markets like the US and China, offering comprehensive insights for informed business decisions.

Transaction brings total financing commitments across Alterra’s fully discretionary IOS funds to over $1.5 billion

Rehovot, Israel, July 16, 2025 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (Nasdaq: STKH) (“Steakholder Foods” or the “Company”), a leading innovator in alternative proteins and 3D printing technologies, today announced the pricing of a public offering of an aggregate of 2,380,954 of the Company’s American Depository Shares (“ADSs”), each representing five hundred (500) ordinary shares of the Company (or ADS equivalents in lieu thereof), and accompanying warrants to purchase up to 2,380,954 of the Company’s ADSs, at a combined public offering price of $1.05 per ADS (or ADS equivalent in lieu thereof) and associated warrant. The warrants will have an exercise price of $1.05 per ADS, will be exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date. The closing of the offering is expected to occur on or about July 17, 2025, subject to the satisfaction of customary closing conditions. 

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.